Abstract
The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Current Molecular Medicine
Title: Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor
Volume: 2 Issue: 8
Author(s): B. K. Patterson, A. Tjernlund and J. Andersson
Affiliation:
Keywords: hiv, lif, cytokines, jak, stat, reverse transcription, transcription, placenta
Abstract: The correlates of protective immunity in HIV-1 infection include the endogenous production of compounds with anti-HIV-1 activity. These compounds can be produced independently of specific humoral or cellular immune responses. A model of compartmental inhibition of HIV-1 infection is the placenta, an organ that prevents transmission of HIV-1 to the fetus in the majority of HIV-1 pregnancies. Studies of this organ elucidated new compounds and mechanisms for prevention and treatment of HIV including the potent inhibitor of HIV-1, leukemia inhibitory factor (LIF). Besides coordinating the humoral and cellular immune responses, cytokines such as IFN-? exhibit intrinsic antiviral activity that represents the first line of defense against pathogens prior to the development of a specific immune response. The study of antiviral factors is particularly important in HIV / AIDS because of the direct destruction of the immune system by HIV-1. In this report, we focus on the identification and mechanism of endogenously produced anti-HIV factors and the overall function of these factors in the prevention and treatment of HIV / AIDS.
Export Options
About this article
Cite this article as:
Patterson K. B., Tjernlund A. and Andersson J., Endogenous Inhibitors of HIV: Potent Anti-HIV Activity of Leukemia Inhibitory Factor, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361817
DOI https://dx.doi.org/10.2174/1566524023361817 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Recent Highlights in the Synthesis of Anti-HCV Ribonucleosides
Current Medicinal Chemistry Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
CNS & Neurological Disorders - Drug Targets Muscular Gene Transfer Using Nonviral Vectors
Current Gene Therapy Synthesis of Imides and Amides from Diacetyl-L-Tartaric Acid Anhydride
Letters in Organic Chemistry Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Macrophage Differentiation to Foam Cells
Current Pharmaceutical Design Editorial (Thematic Issue: Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic Therapy)
Current Pharmaceutical Design HIV-Enhancing Factors Are Secreted by Reproductive Epithelia upon Inoculation with Bacterial Vaginosis-Associated Bacteria
Protein & Peptide Letters Efficacy and Toxicological Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Inhibitors of ER Aminopeptidase 1 and 2: From Design to Clinical Application
Current Medicinal Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Erythropoietin Directly Affects Human Macrophage Functionality
Current Pharmaceutical Biotechnology Angiotensin II and Abdominal Aortic Aneurysms: An update
Current Pharmaceutical Design Interleukin-1β Plays a Role in the Activation of Peripheral Leukocytes after Blood-Brain Barrier Rupture in the Course of Subarachnoid Hemorrhage
Current Neurovascular Research Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention
Current Cardiology Reviews Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar?
Current Drug Targets Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice
Current Molecular Medicine